Trial Profile
Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 20 Sep 2022
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Retinal oedema
- Focus Proof of concept; Therapeutic Use
- Sponsors Kiora Pharmaceuticals
- 24 Jun 2016 Status changed from recruiting to discontinued.
- 13 May 2016 Top-line data from this trial are expected in the second quarter of 2016, according to an Eyegate Pharmaceuticals media release.
- 19 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Aug 2016 ClinicalTrials.gov record.